Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 0.78 |
| ▸ | ITGAV | P06756 | 15/20 | 0.78 |
| ▸ | ITGB5 | P18084 | 8/20 | 0.76 |
| ▸ | ITGA2B | P08514 | 7/20 | 0.76 |
| ▸ | ITGB6 | P18564 | 3/20 | 0.76 |
| ▸ | ITGA5 | P08648 | 3/20 | 0.70 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.70 |
| ▸ | ITGB8 | P26012 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclorgdfv SCHEMBL30636069 | 1.00 | ITGB3 (0.78) | ITGB3ITGAVITGB5ITGA2BITGB6 | |
| SCHEMBL31294830 | 0.92 | ITGB3 (0.80) | ITGB3ITGAVITGB5ITGA2BITGA5 | |
| SCHEMBL30098352 | 0.91 | ITGB3 (0.76) | ITGB3ITGAVITGB5ITGA2BITGA5 | |
| SCHEMBL29464836 | 0.89 | ITGB3 (0.75) | ITGB3ITGAVITGB5ITGA2BITGA5 | |
| SCHEMBL29578997 | 0.89 | ITGB3 (0.75) | ITGB3ITGAVITGB5ITGA2BITGA5 | |
| SCHEMBL29366713 | 0.88 | ITGB3 (0.74) | ITGB3ITGAVITGB5ITGA2BITGA5 | |
| SCHEMBL30129817 | 0.88 | ITGB3 (0.81) | ITGB3ITGAVITGB5ITGA2BITGB6 | |
| SCHEMBL17364341 | 0.88 | ITGB3 (0.74) | ITGB3ITGAVITGB5ITGA2BITGA5 | |
| Cilengitide SCHEMBL19534260 | 0.87 | ITGB3 (0.78) | ITGB3ITGAVITGB5ITGA2BITGB6 | |
| Cilengitide SCHEMBL34082 | 0.87 | ITGB3 (0.78) | ITGB3ITGAVITGB5ITGA2BITGB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 203 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| EP-4642484-A1 | TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| EP-4642492-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| US-20250295821-A1 | TARGETED RADIOPHARMACEUTICAL FOR TUMOR AND ITS USE IN THE IMAGING-GUIDED COMBINATION THERAPY OF TARGETED RADIOTHERAPY AND IMMUNOTHERAPY | BeijingGiluntidePharmaceuticalCo.,Ltd. (CN) | 2025-09-25 | — | — | US | claimed |
| US-12351855-B2 | Bioelectronic circuits, systems and methods for preparing and using them | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2025-07-08 | — | — | US | claimed |
| CN-119896744-A | Application of integrin targeting peptide-collagenase pharmaceutical composition and pharmaceutical composition constructed by same | 中国药科大学 | 2025-04-29 | — | — | CN | claimed |
| CN-119838022-A | Amatoxin conjugates containing branched linkers | 杭州多禧生物科技有限公司 | 2025-04-18 | — | — | CN | claimed |
| US-12220464-B2 | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2025-02-11 | — | — | US | claimed |
| WO-2024239281-A1 | TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE | HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) | 2024-11-28 | — | — | WO | claimed |
| WO-2024240173-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) | 2024-11-28 | — | — | WO | claimed |
| CN-115443134-A | Conjugates of cell binding molecules and camptothecin analogs | 杭州多禧生物科技有限公司 | 2022-12-06 | — | — | CN | claimed |
| US-20220378951-A1 | SPECIFIC CONJUGATION LINKERS, SPECIFIC IMMUNOCONJUGATES THEREOF, METHODS OF MAKING AND USES SUCH CONJUGATES THEREOF | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2022-12-01 | — | — | US | claimed |
| US-20220313836-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2022-10-06 | — | — | US | claimed |
| WO-2022184899-A1 | CELL ATTACHMENT MATERIALS, DEVICES AND USES THEREOF | FACELLITATE GMBH (DE) | 2022-09-09 | — | — | WO | claimed |
| EP-4053163-A1 | CELL ATTACHMENT MATERIALS, DEVICES AND USES THEREOF | FaCellitate GmbH (DE) | 2022-09-07 | — | — | EP | claimed |
| WO-2022133288-A1 | FAP-ACTIVATED RADIOTHERANOSTICS, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE (US) | 2022-06-23 | — | — | WO | claimed |
| EP-3986463-A1 | A CONJUGATE OF A CYTOTOXIC AGENT TO A CELL BINDING MOLECULE WITH BRANCHED LINKERS | Hangzhou Dac Biotech Co., Ltd. (CN) | 2022-04-27 | — | — | EP | claimed |
| WO-2022078524-A2 | SPECIFIC CONJUGATION OF AN ANTIBODY | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2022-04-21 | — | — | WO | claimed |
| US-20220098635-A1 | BIOELECTRONIC CIRCUITS, SYSTEMS AND METHODS FOR PREPARING AND USING THEM | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2022-03-31 | — | — | US | claimed |
| CN-114040779-A | Conjugates of cell binding molecules containing branched linkers and cytotoxic agents | 杭州多禧生物科技有限公司 | 2022-02-11 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250295821-A1 | TARGETED RADIOPHARMACEUTICAL FOR TUMOR AND ITS USE IN THE IMAGING-GUIDED COMBINATION THERAPY OF TARGETED RADIOTHERAPY AND IMMUNOTHERAPY | CD274, ITGB1, ITGA1 | ITGB3 6/4885ITGAV 5/4885ITGB5 22/4885 |
| US-20220313836-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | CD2BP2, DCLRE1A, EPCAM | ITGB3 265/4885ITGAV 791/4885ITGB5 503/4885 |
| US-12220464-B2 | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof | SLC25A1, GCDH, FH | ITGB3 2189/4885ITGAV 2755/4885ITGB5 1545/4885 |
| US-20220378951-A1 | SPECIFIC CONJUGATION LINKERS, SPECIFIC IMMUNOCONJUGATES THEREOF, METHODS OF MAKING AND USES SUCH CONJUGATES THEREOF | SLC25A1, GCDH, FH | ITGB3 2189/4885ITGAV 2755/4885ITGB5 1545/4885 |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | DCLRE1A, CCR3, CCR8 | ITGB3 55/4885ITGAV 549/4885ITGB5 567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.